Carmot begins Phase 2 trial of dual GLP-1/GIP RA CT-868 for the treatment of type 1 diabetes
Carmot Therapeutics has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult...
top of page
Browse by category
Search
Browse by tag
bottom of page